Stelexis Therapeutics
New York
About Stelexis Therapeutics
Stelexis Therapeutics is to become the cancer therapeutics company, through the discovery and development of novel drugs, utilizing its proprietary platform to selectively target pre-cancerous stem cells. The company will initially focus on therapeutics for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $43.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2019)
- Website: stelexis.com
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/stelexis-therapeutics-7375 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.